3 March 2026 - Roche Korea said the expanded health insurance coverage and updated reimbursement criteria for the oral spinal muscular atrophy treatment Evrysdi (risdiplam) took effect last Sunday, introducing a new tablet formulation and allowing two-way switching between therapies.

Evrysdi is the first oral treatment for spinal muscular atrophy that can be administered non-invasively at home. The newly reimbursed tablet form was approved in June 2025 for patients aged two years and older weighing at least 20 kg. Unlike previous versions, the tablets can be stored at room temperature and swallowed with water or dissolved in filtered water, offering greater flexibility for patients attending school or work.

Read Korean Biomedical Review article